Genentech: Press Releases | Monday, Aug 25, 2025

Monday, Aug 25, 2025

Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina

The $700 million undertaking is a part of Genentech and Roche’s $50 billion funding in U.S. manufacturing, infrastructure and R&D

 

The facility will create greater than 1,900 jobs and help the manufacturing of next-generation metabolic medicines, together with therapies for weight problems

 

U.S. Rep.Deborah Ross, Gov. Josh Stein and different native leaders attended the groundbreaking occasion

Holly Springs, N.C. — August 25, 2025 —

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), at present broke floor on its latest U.S. manufacturing website in Holly Springs, North Carolina. This important growth marks the institution of Genentech’s first manufacturing facility on the East Coast. The 700,000-square-foot facility is strategically designed to help manufacturing of the corporate’s future portfolio of metabolic medicines, together with next-generation therapies for weight problems. The occasion was attended by federal, state and native officers, together with U.S. Rep. Deborah Ross, North Carolina Gov. Josh Stein, State Sec. of Commerce Lee Lilley, State Sens. Sydney Batch and Lisa Grafstein, State Rep. Erin Paré, Wake County Commissioner Cheryl Stallings and Holly Springs Mayor Sean Mayefskie.

 

The undertaking will add greater than 400 native manufacturing jobs when the location is operational and greater than 1,500 building jobs through the growth part. Genentech’s preliminary funding in North Carolina is estimated at greater than $700 million, half of a bigger $50 billion dedication to President Trump’s initiatives to spend money on U.S. manufacturing, infrastructure and R&D.

 

The firm chosen Holly Springs, a rising hub for biopharmaceutical innovation, for its extremely expert native workforce, robust tutorial establishments and proximity to different main life science firms within the Raleigh-Durham space.

 

The new facility is predicted to be accomplished and operational by 2029, incorporating trendy biomanufacturing applied sciences, in addition to superior automation and digital capabilities. The future facility will improve manufacturing capability for the corporate’s manufacturing community, whereas enhancing provide chain resilience via a high-volume, high-efficiency but sustainable design. The 100-acre lot contains house for future enlargement.

 

Genentech CEO Ashley Magargee:

“We are proud to break ground on our new manufacturing site in Holly Springs, North Carolina, with its world-class biotech talent, top research institutions and a robust infrastructure that will enable our growth for years to come. With this step, we are taking action to deliver more life-changing medicines to patients faster, contribute to the local economy, and bolster manufacturing and innovation in the U.S.,” Magargee stated.

 

“We are supportive of President Trump’s goal to bring more pharmaceutical manufacturing to the United States and appreciate the work that Commerce Secretary Lutnick and the Department of Commerce’s U.S. Investment Accelerator are doing to remove regulatory barriers that cause delays in establishing manufacturing sites in the U.S. We also thank the North Carolina, Wake County and Holly Springs officials for their partnership. Their warm welcome and leadership in the life sciences bodes well for great things to come for our company, your communities, and, ultimately, for patients.”

 

U.S. Rep. Deborah Ross, 2nd North Carolina Congressional District:

“This groundbreaking is a milestone for our community and for North Carolina’s growing role in the biotech economy. Investments like this one mean good-paying jobs for our residents, expanded opportunities for workers with a range of skills and education, and continued growth for the Research Triangle’s innovation ecosystem. I look forward to working with Genentech to ensure this facility helps our region to thrive for decades to come.”

 

North Carolina Gov. Josh Stein:

“North Carolina has earned its reputation as the best state for business, and Genentech’s decision to put down roots in Holly Springs is further proof of our leadership in the biotech sector. From our top-tier research universities to our world-class workforce, North Carolina has exactly what companies need to succeed. I am pleased to welcome Genentech to Holly Springs as they expand their operations to the East Coast.”

 

Holly Springs Mayor Sean Mayefskie:

“The groundbreaking of Genentech’s new facility marks a defining step ahead for Holly Springs. Not solely does it strengthen Holly Springs’ function as a cornerstone in North Carolina’s life sciences manufacturing ecosystem, however we anticipate to see a strong increase to our native economic system, significantly for small companies. We are thrilled for Genentech to be a part of our neighborhood!”

 

About Genentech

Founded nearly 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

 

###